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A B S T R A C T
Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by disseminated thrombotic occlusions of
the microcirculation. Identification of ADAMTS13 protease and its place in the pathophysiology of TTP led to better un-
derstanding of the disease and better survival for the diseased. Here we show a case report of a patient that had a normal
ADAMTS13 protease activity and an unusual clinical presentation and utilize that case to highlight how the absence of a
severe ADAMTS13 protease deficiency does not preclude a diagnosis of TTP and how early initiation and continuation
of plasma exchange therapy can lead to a positive outcome, even in a severely ill patient. Even though ADAMTS13 prote-
ase determination has no immediate influence on the decision whether or not to start the plasma exchange therapy, it has
great impact on future management of the patient and should be determined whenever possible.
Key words: thrombotic thrombocytopenic purpura, ADAMTS13 protease, plasma exchange therapy
Introduction
Thrombotic thrombocytopenic purpura (TTP) was
first described by Moschcowitz in 1924. It is a disease
characterized by disseminated thrombotic occlusions of
the microcirculation, clinically described as being distin-
guished by a pentad of symptoms: microangiopathic he-
molytic anemia, thrombocytopenia, neurological symp-
toms, fever and renal dysfunction. However, lately fewer
patients are described presenting with fever and severe
neurological symptoms1, which is probably due to the
early start of treatment, shown to be crucial for the suc-
cess of the therapy. Until 1991 the mortality of TTP was
around 90%2, and there were just anecdotal evidence
that plasma infusions might improve chances of survival
in these patients. A pivotal study was done by the Cana-
dian Apheresis Study Group that showed superiority of
plasma exchange therapy over plasma infusion, with
overall mortality of 29% in both groups, mortality in
plasma exchange group being 21%3. Pathogenesis of the
disease was unknown until 1997, when acquired antibod-
ies were first identified in adults with TTP that inhibit
von Willebrand factor (vWF) cleaving protease, which is
normally found in plasma and is responsible for cleaving
large multimeres of vWF that are otherwise capable of
agglutinating circulating platelets4,5. It was also found
that there is a subset of patients with familiar throm-
botic thrombocytopenic purpura that lacked vWF-cleav-
ing protease activity but had no inhibitor. In 2001
vWF-cleaving protease was purified and cloned, it was
shown to be a new member of the »a disintegrin and
metalloprotease with thrombospondin type 1 repeats«
family, and named ADAMTS13 protease6–10. There was a
lot of excitement generated, because now pathogenesis of
TTP could finally be explained: autoantibodies are gen-
erated against ADAMTS13 protease, and the absence of
ADAMTS13 protease activity allows VWF and platelets
to accumulate in microvascular thrombi, which leads to
platelet consumption, hemolysis, and microvascular oc-
clusion, leading to infarction damage of brain and kidney.
Plasma exchange is efficacious because it removes
pathoenic autoantibodies and replenishes the missing
ADAMTS13 protease, restoring the normal regulation of
VWF-dependent platelet adhesion. However, reality pro-
ved not to be as simple. In the following years a lot of
studies were done looking into activity of ADAMTS13
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protease in various populations and their response to
plasma exchange therapy11–14. Studies have confirmed
the specificity of severe ADAMTS13 protease deficiency
(<5%) for idiopathic TTP, but sensitivity remains contro-
versial. Severe ADAMTS13 deficiency is rare in »second-
ary« TTP, associated with hematopoietic stem cell trans-
plantation, cancer, pregnancy, systemic infections, drug
toxicity, or other predisposing conditions, and it was not
shown in diarrhea-associated hemolytic uremic syndro-
me (HUS) caused by Shiga toxin–producing E. coli1,12. In
that respect, determination of ADAMTS13 protease defi-
ciency rules out the possibility of secondary TTP, and
proves beyond suspicion the diagnosis of idiopathic TTP.
However, the incidence of severe ADAMTS13 protease
deficiency in patients with idiopathic TTP has varied
from 33% to 100% in different studies1,4,5,14. Further-
more, even patients with shown severe ADAMTS13 pro-
tease deficiency can achieve clinical responses with plas-
ma exchange therapy despite persistent low ADAMTS13
protease activity15. It is important to emphasize that pa-
tients regardless of their ADAMTS13 protease activity
status will equally respond to plasma exchange therapy1.
A difference in early response to therapy and survival be-
tween two groups has not yet been shown, but there is
evidence that severe ADAMTS13 protease deficiency and
high antibody titers are associated with delayed response
to plasma exchange therapy and increased risk of relap-
se15–18. Relapse is frequent in TTP, rates about 30–35%,
but there has been shown statistically significant differ-
ence in the frequency of relapses in the patients with se-
vere ADAMTS13 deficiency1. Even though ADAMTS13
protease determination has no immediate influence on
the decision whether or not to start the plasma exchange
therapy, it certainly has great impact on future dealings
with the patient. As shown, if ADAMTS13 deficiency is
found, the diagnosis of TTP has been proven with cer-
tainty, and we need not look any further trying to find
causes of secondary TTP. Also, such a patient should be
closely monitored for relapse and in the case of throm-
bocytopenia with elevated lactate dehydrogenase (LDH),
plasma exchange therapy should be promptly started in
order to avoid organ tissue damage.
The purpose of presenting this case is to highlight
how the absence of a severe ADAMTS13 protease defi-
ciency does not preclude a diagnosis of TTP and how
early initiation and continuation of plasma exchange
therapy can lead to a positive outcome, even in a severely
ill patient.
Case Report
The patient is a 61 year old female, with no other ill-
nesses apart from hypertension, initially presented with
symptoms of fever up to 40°C, with chills, general poor
condition and abdominal pain present for three days. She
was then seen by an infectious disease physician. Initial
work-up showed thrombocytopenia of 75x109/L, but no
clinical findings indicated infectious etiology. She was re-
ferred to internal medicine specialist in an outside clinic.
Platelet count at that point was 17x109/L, LDH was ele-
vated. No anemia was present. She was conscious, but
slow in response. During the next days non-oliguric
acute renal failure developed. After platelet (PLT) substi-
tution a kidney biopsy was performed and hemodialysis
started. Histological examination showed extensive tu-
bular damage with focal eccentric accumulation of hya-
line material in walls of some artheriolas. These findings
were indicative of TTP, so plasma exchange and steroids
were initiated, and she was started on iv. antibiotics be-
cause of fever, although there were no sings of infection.
Progression of alteration in mental status dominated the
further clinical presentation, she became confused, al-
tered, but without sings of focal damage, and CT scan
was normal. Of note is, that the microimmunofloures-
cent test for antiplatelet antibodies was positive, both di-
rect and indirect. The patient was then transferred to
our intensive care unit for further treatment.
Upon admission to our clinic her mental status had
deteriorated, she was somnolent, reacting only to painful
stimuli, with numerous hematoma on extremities. Blood
pressure was somewhat higher 160/90 mmHg, pulse was
94/min, she was still febrile, although not over 38.4oC.
Initial lab work-up showed leukocytosis with 7% of non-
-segmented granulocytes, moderate anemia (hemoglobin
110g/L, erythrocytes 3.55x109/L) with schistocytes on the
peripheral blood smear, platelet count was 62x109/L. Se-
rum creatinine was elevated (465 mmol/L), urea was 25.1
mmol/L, she had mild elevation of both conjugated and
unconjugated bilirubin (16 mmol/L and 7 mmol/L, respec-
tively) and of liver enzymes (AST 138 U/L, ALT 143 U/L,
GGT 135 U/L). LDH was elevated (503 U/L), haptoglobin
was within normal ranges (0.67g/L). Coombs test was
negative. Fibrinogen degradation products were elevated
(D-dimers were 5.34 mg/L) and fibrinogen decreased (1.8
g/L), with normal prothrombin time (0.9) and activated
partial thromboplastin time (APTT) (28.2 s). C-reactive
protein (CRP) was low, which was indicative of non-infec-
tious origin of fever. Blood cultures were also done re-
peatedly, and were all negative. All other microbiological
samples did not indicate infectious etiology, including
cytomegalovirus (CMV) early antigen test. There was no
evidence of malignant disease found. Initial immunology
tests were done and showed no signs of autoimmune dis-
ease (antinuclear factor (ANF) negative, rheumatiod fac-
tor (RF) 9.75, anti-neutrophil cytoplasmic antibody
(ANCA) negative, complement components tested were
with in normal range). ADAMTS13 protease activity was
determined and it was normal (64% and 60% activity), of
note is that serum for testing was obtained after 2 ses-
sions of plasma exchange had been done.
Daily plasma exchange was continued, along with
immunosuppressive therapy (methylprednisolone 80 mg
iv. daily). Her condition did not improve during the first
week; it actually worsened, hemoglobin level fell from
>100 g/L to <60 g/L warranting packed erythrocyte
transfusion, and her state of consciousness deteriorated.
There was modest improvement around day 6 from ad-
mission, PLT count rose to >75x109/L, but improvement
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was transient. At that time she was conscious, but agi-
tated, and transiently confused. There were hints of alco-
hol abuse, and alcohol withdrawal crisis was also consid-
ered. On day 12 the patient received 2mg of vincristine iv,
to be continued in weekly applications. On day 19 PLT
count was around 70x109/L, and around day 24, after the
second application of vincristine, there was considerable
improvement in PLT count (92x109/L), and plasma ex-
change procedure could be tapered. Around that time the
patient started to feel better and her mental status im-
proved. Treatment was continued with weekly vincristi-
ne injections, corticosteroids and plasma exchange ther-
apy were tapered, and the state of the patient further
improved (Figure 1). She was released on day 40 after ad-
mission, after receiving total of 27 plasma exchanges,
and 5 weekly injections of vincristine (2mg/injection).
Before release her PLT count was 169x109/L, hemoglobin
was 79 g/L, Htc 0.241, creatinine 129 mmol/L, LDH 246
U/L. She continued with regular follow up visits, her he-
moglobin level improved shortly after discharge, she did
not need red blood cell substitution. In the follow up pe-
riod of 2 years she had no relapses.
Discussion and Conclusion
Even though the pathogenesis of TTP is explained,
and ADAMTS13 protease assay is widely available, we
still rely predominantly on clinical symptoms when es-
tablishing the diagnosis of TTP. Nowadays, the pentad of
symptoms is rarely encountered, and since early therapy
initiation is crucial for therapy success, it is generally be-
lieved that evidence of microangiopathic hemolytic ane-
mia (schistocytes, increased serum levels of lactate dehy-
drogenase, indirect bilirubin, and a negative direct
Coombs’ test) and thrombocytopenia are sufficient to
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Fig. 1. Overwiev of therapy administered. PLT – platelets, Hb – hemoglobin, FFP – fresh frozen plasma, po – per os.
TABLE 1
OVERVIEW OF TYPES OF THROMBOTIC THROMBOCYTOPENIC PURPURA
Category Clinical Features* Mechanism / ADAMTS13 Treatment
Idiopathic TTP Coombs negative, absence of condi-
tions associated with secondary
TTP. Severe renal failure is rare.
Autoimmune ADAMTS13 defi-
ciency in a majority of patients
>80% response to plasma ex-
change. Consider
immunosuppression
Secondary TTP Associated conditions include can-
cer, infection, hematopoietic stem
cell transplantation, solid organ
transplantation, SLE, chemother-
apy, certain drugs (ticlopidin)
Mechanisms are mostly unknown.
ADAMTS13 deficiency is rare. With
SLE severe ADAMTS13 deficiency
described
Not likely to respond to plasma ex-
change therapy. Treatment and




Acute renal failure, preceded by
bloody diarrhea.
Endothelial damage by Shiga
toxin–producing E. coli.
ADAMTS13 deficiency is rare
No demonstrated efficacy of plasma
exchange.
Atypical HUS Acute renal failure, no diarrhea Complement regulatory protein de-
fects in at least 50% of patients;
ADAMTS13 deficiency is rare
No demonstrated efficacy of plasma
exchange, except possibly for factor
H deficiency
*Other than microangiopathic hemolytic anemia and thrombocytopenia, TTP – thrombotic thrombocytopenic purpura, HUS – Hemo-
lytic-uremic syndrome, SLE – systemic lupus erythematosus, ADAMTS13 – a disintegrin and metalloprotease with thrombospondin
type 1 repeats
consider a diagnosis of TTP, particularly in the absence of
signs and symptoms indicative of secondary cause, such
as sepsis, malignant disease, pregnancy, or malignant hy-
pertension (Table 1). Our patient had somewhat unusual
initial presentation: abdominal pain, high fever with
chills and thrombocytopenia without considerable ane-
mia. When developed renal failure, physicians from an
outside clinic performed kidney biopsy, not usually done
to establish diagnosis of TTP, but it was still helpful. It
was not until she was transferred to our intensive care
unit that she became somnolent, and there were signs of
intravascular destruction of platelets and Coombs-nega-
tive microangiopathic hemolytic anemia, which assured
us it was a case of TTP. Misleading were the positive re-
sult of antiplatelet antibodies, and an anamnesis of high
fever and chills, which are more indicative of infection,
although all cultures taken were sterile, CRP was not el-
evated and there was no evidence of pneumonic infiltraion
or any other infection. We relied on clinical presenation
and continued plasma exchange therapy; severe anemia
that developed later only proved to our opinion the initial
working diagnosis. Absence of a severe ADAMTS13 pro-
tease deficiency did not influence our diagnosis or our
treatment plan; as it was shown not all patients with
TTP have decreased ADAMTS13 protease activity and it
should not be an exclusion factor in the diagnosis of TTP.
Even though ADAMTS13 protease analysis was done af-
ter at least 2 plasma exchange sessions, we believe that
this patient had no decreased ADAMTS13 protease activ-
ity, since generally more plasma exchange therapies are
needed to eliminate antibodies and reinstitute metallo-
protease activity15.
In conclusion, thrombotic thrombocytopenic purpura
is a disease in which a considerable progress was made in
deciphering the pathogenesis, improving therapy options
and patients’ chances of survival. Today clinicians, when
considering TTP as diagnosis, still mostly rely on the
presence of thrombocytopenia and microangiopathic he-
molytic anemia, and the absence of other causes for it. In
the case of our patient we eliminated most of the more
frequent causes for secondary TTP: malignant disease,
pregnancy, toxic effect of drugs, systemic infection, and
also could not prove that it was a case of idiopathic TTP.
We do agree that ADAMTS13 deficiency determina-
tion is needed and necessary, and plasma should be taken
for testing prior to starting plasma exchange therapy.
Negative result does not exclude TTP diagnosis, but posi-
tive one reassures clinicians of their suspected diagnosis
and is an important piece of information when planning
future care for the patient in question.
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TROMBOTSKA TROMBOCITOPENI^NA PURPURA – ULOGA TESTA ADAMTS13 PROTEAZE U
KLINI^KOJ PRAKSI
S A @ E T A K
Trombotska trombocitopeni~na purpura (TTP) je bolest karakterizirana diseminiranin trombotskim okluzijama
mikrocirkulacije. Identifikacija ADAMTS13 proteaze i njenog mjesta u patofiziologiji bolesti dovelo je do boljeg razu-
mijevanja bolesti i boljeg pre`ivljenja oboljelih. Ovaj rad je prikaz slu~aja bolesnica s normalnom razinom ADAMTS13
aktivnosti i neobi~nom klini~kom prezentacijom uz pomo} kojega `elimo naglasiti kako odsustvo te{kog pomanjkanja
ADAMTS13 aktivnosti ne izuzima dijagnozu TTP i kako rano zapo~injanje i nastavak terapije izmjenom plazme mo`e
dovesti do pozitivnog ishoda, ~ak i u te{ko oboljelih. Iako odre|ivanje nedostatka ADAMTS13 aktivnosti nema trenutni
utjecaj na odluku da li ili ne zapo~eti terapiju izmjenom plazme, ima veliki utjecaj na daljnje terapijske odluke i trebala
bi biti poku{ana kad god je to mogu}e.
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